{"result": "(\"entity\"<|>FDA<|>ORGANIZATION<|>The FDA (Food and Drug Administration) is a federal agency responsible for protecting public health by regulating food, drugs, and other related products in the United States.)\n##\n(\"entity\"<|>EMA<|>ORGANIZATION<|>The EMA (European Medicines Agency) is an agency of the European Union responsible for the evaluation and supervision of medicinal products.)\n##\n(\"entity\"<|>BLOSSOM<|>EVENT<|>The BLOSSOM study is a clinical trial evaluating the efficacy of lorcaserin for obesity management, involving 4008 subjects.)\n##\n(\"entity\"<|>BLOOM<|>EVENT<|>The BLOOM study is a clinical trial assessing the effectiveness of lorcaserin for overweight and obesity management over two years.)\n##\n(\"entity\"<|>BLOOM-DM<|>EVENT<|>The BLOOM-DM study is a clinical trial focused on the effects of lorcaserin for obesity management in patients with diabetes, involving 604 participants.)\n##\n(\"entity\"<|>LORCASERIN<|>ORGANIZATION<|>Lorcaserin is a medication used for weight management, evaluated in several clinical trials for its efficacy and safety.)\n##\n(\"entity\"<|>FENTERMINE<|>ORGANIZATION<|>Fentermine is a medication used to reduce appetite in patients with obesity, approved for use in 1956.)\n##\n(\"entity\"<|>TOPIRAMATE<|>ORGANIZATION<|>Topiramate is a medication approved for the treatment of partial seizures and migraine prophylaxis, also used in combination with fentermine for weight management.)\n##\n(\"relationship\"<|>BLOSSOM<|>FDA<|>The BLOSSOM study was evaluated and approved by the FDA for its clinical significance in obesity management<|>7)\n##\n(\"relationship\"<|>BLOOM<|>FDA<|>The BLOOM study was evaluated and approved by the FDA for its clinical significance in obesity management<|>7)\n##\n(\"relationship\"<|>BLOOM-DM<|>FDA<|>The BLOOM-DM study was evaluated and approved by the FDA for its clinical significance in obesity management in diabetic patients<|>7)\n##\n(\"relationship\"<|>LORCASERIN<|>BLOSSOM<|>Lorcaserin was the primary medication evaluated in the BLOSSOM study for its effectiveness in weight management<|>8)\n##\n(\"relationship\"<|>LORCASERIN<|>BLOOM<|>Lorcaserin was the primary medication evaluated in the BLOOM study for its effectiveness in weight management<|>8)\n##\n(\"relationship\"<|>LORCASERIN<|>BLOOM-DM<|>Lorcaserin was the primary medication evaluated in the BLOOM-DM study for its effectiveness in weight management in diabetic patients<|>8)\n##\n(\"relationship\"<|>FENTERMINE<|>TOPIRAMATE<|>Fentermine and topiramate are combined in a medication approved for weight management<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: y eficacia de lorcaserina han sido                      FDA, pese a su eficacia modesta, debido a su bajo\nevaluadas en tres ensayos clínicos aleatorizados doble                      perfil de riesgo. Sin embargo, la EMA no ha conside-\nciego frente a placebo. El Estudio BLOSSOM (Behavio-                        rado su comercialización debido a la falta de especifi-\nral Modification and Lorcaserin Second Study for Obe-                       cidad de los receptores de serotonina capaces de in-\nsity Management)6  incluyó 4008 sujetos con obesidad                        crementar de alguna manera síntomas depresivos,\no sobrepeso a recibir lorcaserina 10 mg/día (n = 801),                      síndrome serotoninérgico e incluso afectación valvu-\n10 mg/2 veces al día (n = 1602) o placebo (n = 1601)                        lar. Además, quedan sin aclarar los potenciales ries-\ndurante 52 semanas. La tasa de pérdidas de abando-                          gos de carcinogenicidad apreciados en animales de\nnos fue del 45%. La pérdida de peso absoluta fue de                         experimentación (carcinoma de mama, astrocitoma y\n5,8 kg, 4,7 kg y 2,9 kg, para cada uno de los grupos de                     schwannoma, entre otros).\nintervención, respectivamente. Más pacientes asigna-                           Contraindicaciones y precauciones:             gestación, lac-\ndos al grupo de lorcaserina 10 mg/día (47,2%), lorca-                       tancia, síndrome serotoninérgico o síndrome neurolép-\nserina 10 mg x 2 veces/día (40,2%) perdieron ≥ 5% del                       tico maligno10. Faltan datos de su posible empleo en\npeso corporal al finalizar un año de tratamiento en                         pacientes con depresión. Tampoco se conocen las inte-\ncomparación con el placebo (25%).                                           racciones con otros inhibidores selectivos de la recap-\n   El estudio BLOOM (Behavioral Modification and Lor-7                      tación de serotonina, IMAO, hierba de San Juan. Evitar\ncaserin for Overweight and Obesity Management)                              en pacientes con hepatopatías o enfermedad renal cró-\nevaluó a 3182 pacientes durante 2 años (50% de                              nica avanzada; precaución también en aquellos con\nabandonos) con resultados similares (–5,8 kg para lor-                      valvulopatías, insuficiencia cardiaca, bradicardia o blo-\ncaserina frente a –2,2 kg del grupo placebo). El tercer                     queo cardiaco10.\nestudio, más pequeño, BLOOM-DM (Behavioral Modi-\nfication and Lorcaserin for Obesity and Overweight                          2.2.   Combinación de fentermina y topiramato\nManagement in Diabetes Mellitus)8 , incluyó a 604 pa-                              (Qsymia®)\ncientes con diabetes (34% de abandonos). La pérdida\nde peso fue más escasa (–4,7 kg o 3,2%), mientras que                          La combinación de fentermina y topiramato (FEN/\nel 37,5% frente al 16,1% del grupo placebo consiguie-                       TPM) fue aprobada por la FDA en 2012. La fentermina\nron perder ≥ 5% del peso inicial. Aproximadamente la                        es un agente noradrenérgico que se comercializó en\nmitad de los diabéticos alcanzaron concentraciones de                       1956 como monoterapia (15-30 mg/día) para reduc-\nHbA1c < 7%. Globalmente, en comparación con pla-                            ción del apetito en pacientes con obesidad por un\ncebo, los estudios de metanálisis indican que lorcaseri-                    tiempo limitado (inferior a 12 semanas). El tratamiento\nna presenta una odds ratio (OR) de 3,10 (IC 95%: 2,38-                      con topiramato (200-400 mg/día) se aprobó en 1996\n4,05) de alcanzar una pérdida ≥ 5% del peso9.                               para las crisis comiciales parciales y en 2004 para la\n   Los efectos secundarios más importantes fueron                           profilaxis de las migrañas. TPM es capaz de reducir el\nnáuseas, cefaleas, mareos, astenia, estreñimiento y                         apetito al antagonizar los receptores del glutamato\nboca seca. El fármaco fue aprobado en 2012 por la                           (agente orexígeno), inhibe también la anhidrasa carbó-\n---\n                                                                  Tema 8.    Tratamiento farmacológico de la obesidad               135\n\n\n\nnica y aumenta la actividad del ácido gamma-amino-                  hiperclorémica, alteraciones hepáticas o renales. Em-\nbutírico (GABA).                                                    peoramiento       cognitivo     si se   emple\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}